Novo Nordisk A/S | NOVOB - Selling And Administration Expenses

Stock Price
367.80
Daily Change
-5.30 -1.42%
Monthly
6.07%
Yearly
-37.93%
Q1 Forecast
351.07

Novo Nordisk reported DKK18.85B in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.





Selling And Administration Expenses Change Date
Bausch Health Companies USD 795M 99M Sep/2025
Bristol-Myers Squibb USD 1.79B 76M Sep/2025
Eli Lilly USD 2.74B 12.3M Sep/2025
GlaxoSmithKline GBP 2.16B 19M Sep/2025
Merck USD 2.63B 0 Sep/2025
Novartis USD 3.31B 134M Sep/2025
Novo Nordisk DKK 18.85B 2.74B Jun/2025
Novo Nordisk DKK 2.86B 13.25B Jun/2025
Pacira USD 91.8M 14.6M Sep/2025
Sanofi EUR 2.75B 455M Dec/2025
Supernus Pharmaceuticals USD 179.68M 117.46M Sep/2025